Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.

ABSTRACT:

Background

To compare the efficacy and toxicity of peptide-doxorubicin (PDOX) and doxorubicin (DOX) on nude mice models of human gastric cancer.

Results

Both PDOX and DOX could significantly inhibit tumor growth compared with Control (P < 0.05) in both subcutaneous and orthotopic models. Animal survival was much better in PDOX group than DOX group. In peripheral blood test, PDOX group had significantly higher levels of platelets than the Control (P < 0.05), and lymphocyte lower than Control (P < 0.05). There were no significant differences on liver, kidney and cardiac function parameters among three groups (P > 0.05). Immunohistochemistry showed that treatment groups had much higher Tunel than Control (P < 0.05), and PDOX had significantly

SUBMITTER: Zhang J 

PROVIDER: S-EPMC5788612 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature